Compugen (CGEN) Competitors $2.06 -0.05 (-2.37%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$1.97 -0.09 (-4.37%) As of 05:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEN vs. BCYC, AQST, MBX, NAGE, ZVRA, ORGO, CTMX, MLTX, CRVS, and ETONShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Bicycle Therapeutics (BCYC), Aquestive Therapeutics (AQST), MBX Biosciences (MBX), Niagen Bioscience (NAGE), Zevra Therapeutics (ZVRA), Organogenesis (ORGO), CytomX Therapeutics (CTMX), MoonLake Immunotherapeutics (MLTX), Corvus Pharmaceuticals (CRVS), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Compugen vs. Its Competitors Bicycle Therapeutics Aquestive Therapeutics MBX Biosciences Niagen Bioscience Zevra Therapeutics Organogenesis CytomX Therapeutics MoonLake Immunotherapeutics Corvus Pharmaceuticals Eton Pharmaceuticals Compugen (NASDAQ:CGEN) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Do analysts prefer CGEN or BCYC? Compugen presently has a consensus price target of $4.00, indicating a potential upside of 94.17%. Bicycle Therapeutics has a consensus price target of $22.22, indicating a potential upside of 164.87%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer CGEN or BCYC? In the previous week, Bicycle Therapeutics had 5 more articles in the media than Compugen. MarketBeat recorded 10 mentions for Bicycle Therapeutics and 5 mentions for Compugen. Bicycle Therapeutics' average media sentiment score of 0.64 beat Compugen's score of 0.56 indicating that Bicycle Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, CGEN or BCYC? Compugen has higher revenue and earnings than Bicycle Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M6.60-$14.23M-$0.22-9.36Bicycle Therapeutics$19.28M30.16-$169.03M-$3.51-2.39 Which has more risk & volatility, CGEN or BCYC? Compugen has a beta of 2.61, suggesting that its share price is 161% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Is CGEN or BCYC more profitable? Compugen has a net margin of -87.45% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Compugen's return on equity.Company Net Margins Return on Equity Return on Assets Compugen-87.45% -34.77% -16.82% Bicycle Therapeutics -1,257.00%-32.43%-26.80% Do institutionals and insiders believe in CGEN or BCYC? 12.2% of Compugen shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryBicycle Therapeutics beats Compugen on 10 of the 16 factors compared between the two stocks. Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.29M$3.36B$6.11B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-9.3622.7785.3627.36Price / Sales6.60486.00596.99137.58Price / CashN/A46.7037.4661.86Price / Book3.3210.5512.286.81Net Income-$14.23M-$52.58M$3.32B$276.80M7 Day Performance7.29%0.09%0.59%0.42%1 Month Performance49.28%15.61%10.54%7.86%1 Year Performance21.18%15.13%70.62%41.24% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen1.3913 of 5 stars$2.06-2.4%$4.00+94.2%+26.4%$188.29M$27.86M-9.3670BCYCBicycle Therapeutics3.9214 of 5 stars$8.23-1.7%$22.22+170.0%-69.0%$580.09M$35.28M-2.34240News CoverageAnalyst ForecastAQSTAquestive Therapeutics2.6092 of 5 stars$5.97+2.9%$10.29+72.3%+50.1%$578.40M$57.56M-8.53160MBXMBX Biosciences2.8065 of 5 stars$16.26-2.6%$39.88+145.2%N/A$560.68MN/A-3.58N/AAnalyst ForecastGap UpNAGENiagen Bioscience3.0728 of 5 stars$7.26+4.8%$13.42+84.8%N/A$552.69M$116.30M34.57120ZVRAZevra Therapeutics2.6236 of 5 stars$10.65+9.2%$24.00+125.4%+40.6%$547.32M$23.61M-50.7120Analyst ForecastORGOOrganogenesis3.75 of 5 stars$4.20-2.1%$7.33+74.6%+27.2%$544.22M$482.04M-30.00950CTMXCytomX Therapeutics4.2398 of 5 stars$3.28-0.6%$5.42+65.1%+204.5%$544.21M$138.10M5.86170MLTXMoonLake Immunotherapeutics2.9167 of 5 stars$8.66+2.7%$37.00+327.3%-79.4%$541.47MN/A-3.122Trending NewsGap UpCRVSCorvus Pharmaceuticals2.2089 of 5 stars$6.98-2.9%$13.00+86.2%+14.4%$535.76MN/A-6.9130Analyst ForecastETONEton Pharmaceuticals2.6991 of 5 stars$20.73+4.0%$29.67+43.1%+127.6%$534.47M$39.01M-129.5620 Related Companies and Tools Related Companies Bicycle Therapeutics Alternatives Aquestive Therapeutics Alternatives MBX Biosciences Alternatives Niagen Bioscience Alternatives Zevra Therapeutics Alternatives Organogenesis Alternatives CytomX Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Corvus Pharmaceuticals Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
